Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT05572684 (https://clinicaltrials.gov/show/NCT05572684)
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
Study Contact Information:
About the Study
NOTE: This study is no longer recruiting people.
This study will test the safety and effectiveness of a new immunotherapy drug called NC410 used in combination with the immunotherapy agent Keytruda (pembrolizumab) in people with advanced or metastatic cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:
- have a tumor marker known as microsatellite stable (MSS), OR
- have been treated with and no longer respond to treatment with immunotherapy drugs known as immune checkpoint inhibitors.
This Study is Open To:
NOTE: This study is no longer recruiting people.
This Study is Not Open To:
NOTE: This study is no longer recruiting people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.